Member Info for Mars1

Bod said they would not start ceo search until data was received ie because anyone worth their salt would not join unless data was good. So started Dec? Or after new year? Future of co certain!

Thought BD had been covered off at least for 002 and 004 ignored. Is similar background to AB required one who has developed and then marketed sowe can continue to progress development.

Azerion alone is huge, Xaxis should more than double revenue
“ Azerion is one of Europe’s leading digital entertainment and media platforms, combining owned and operated content, that serves the needs of two groups of customers globally at scale:
Advertisers: Azerion’s advertising technology provides advertisers with maximum engagement with hundreds of millions of players and consumers, generating strong brand performance and measurable results in a brand safe environment; and
Consumers: Azerion’s platform features some of the most popular global social gaming franchises, including the immersive multiplayer games Habbo Hotel and Hotel Hideaway, the social poker game Governor of Poker, along with a portfolio consisting of 16,000+ game titles and 425+ million unique monthly active users across all its products, including through its digital publisher network.”

In fact we haven’t had an update on 002 the only notification was the bus dev appointment for 002

Must be due an update soon on 004 unless the wording used by AR in the RNS of 8/2 was not correct where he said they continue to make significant progress in both 004 and 002, as the last update for 004 was the patent submission notified 12/11.

Would have thought they would RNS 004 drug rather than it be found out by default, opportunity to put spin on the good results last year. All indications I see, on the website, in interviews (early licensing policy, working with licensees) , what is not said in RNS ie no business dev, suggest to me originator has been contacted. Looking forward to news.

From the RNS 14/12 referring to the use of Lanstead monies both 002 and 004
“ o Business development activities with potential licensees for both assets; and”
What was a clear message yesterday in the RNS is that no BD activity is required for 004. The website is clear also regarding next steps for 004 regarding liscense discussions with the originator and the RNS 8/2 said there was continuing significant progress.

Well in a fashion we have had an 002 update BD guy in place will chase licensing and expect the durability update soon. We still await the 004 update regarding significant progress from 8/2 RNS. For some reason 004 does not require BD.

Specifically 002 no BD required on 004

Soup yes that seems about right there is also track 1 which is about 6 months but I don’t know what the qualifications are for that route other than higher fees. I think I recall the original drug had a short period left under license (1 year?). What are the chances the originator will want to progress 004 in tandem with the patent approval? If interested it should be a low risk option in terms of cost if no or limited financial impact until patent approval.

Soup do you know the timescale for patent approval?

From the website there is the potentially increase their patent protection
“ If the patent applications on these new forms are granted, there is potential for patent expiry to extend to 2040/2041
We will seek to license NXP004 to the originator of the marketed drug to potentially extend their patent protection, potentially adding significant value for the originator.”

Not sure if the website indicates license outsourcing following patent application or award

Yes 004 value will only exist with the patent, any deal can be done subject to the 2nd patent, could even be the first milestone payment. Little risk as 1st patent was approved ie a precedent exists

Soup thanks I thought the normal process was the application is given a reference, only the applicant can then track progress. Once the patent is approved then anyone can object to the award but there is a 28 day window to do so. Once the patent has been submitted and the number issued obviously sequential copy applications would fail where I thought the risk existed.
I should imagine if the originator has been approached they may be keen to get another 20 year run under license so support the patent application.

Had a curious thought but maybe just missing the point, why keep 004 under wraps now the 2nd patent has been submitted. Thought the purpose was to license 004, I know the plan is to offer it to the originator but does it need to be secret squirrel, surely you sell something by letting the market know it’s available. 1st refusal is ok as long as it is market rate but it does delay the rest of the market pitch.

Soup thanks bit like watching paint dry. This from the RNS of 12th Nov gives me hope the originator of 004 will be interested where the results show performance improvement over the original. That would make 004 the preferred buy in that space.
“ We are pleased to have filed this new patent application for NXP004. Data that we have generated on these new co-crystal forms in the past six months has shown improvements over the marketed form that justifies filing this new application. ”

Interesting sp still down, more buys than sells sp used to go up

Looking forward to news

Filter agree, the auditors need a reason to resign they have used this, to cut a small unprofitable account. Difficult to load charges when activity is limited.